GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Scope Fluidics SCP.WA · PLN

Health Care · GPW · 🇵🇱 Poland

Compare

142.80

-0.14%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Scope Fluidics

Its shares trade on GPW under the ticker SCP.WA. It has been listed since 16 August 2017. In the fiscal year to 31 December 2025, it reported revenue of PLN 100,000 and a net loss of PLN 46.4m. At that date it held total assets of PLN 195.9m and shareholders' equity of PLN 162.4m.

Scope Fluidics SA engages in the research and development in the field of healthcare. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2017-08-16. The firm focuses on diagnostic and med-tech solutions. The company develops disposable microfluidic systems for the collection of micro-samples of blood, as well as storage of reagents for diagnostic markers. Its projects include PCR ONE system that delivers the bacterial and viral pathogen detection, and BacterOMIC system that delivers information on bacterial susceptibility to antibiotics and on the resistance mechanisms. The firm provides access to laboratories and workshops for developed projects, as well as administrative facilities and services, including financing. In addition, it cooperates with doctors, medical personnel, project managers, engineers and academics.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
16 Aug 2017
Employees
30

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Scope Fluidics SA develops disposable microfluidic systems for blood sample collection in Warsaw.
  • The PCR ONE system detects bacterial and viral pathogens effectively in diagnostics.
  • BacterOMIC system provides bacterial susceptibility information to antibiotics in healthcare.

Weaknesses

  • Scope Fluidics SA has only 30 employees in the Health Care sector in Poland.
  • The company's IPO was on 16 August 2017, limiting recent growth opportunities.
  • Limited workforce of 30 employees may hinder rapid expansion in diagnostics.

Opportunities

  • Collaboration with doctors and medical personnel in Warsaw enhances diagnostic solutions.
  • Cooperation with academics and engineers supports innovative med-tech projects.
  • Access to laboratories and workshops in Warsaw aids project development.

Threats

  • Competition in the Health Care sector in Poland may impact Scope Fluidics SA.
  • The limited number of employees could lead to challenges in scaling operations.
  • Dependence on diagnostic market trends might affect business stability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.